Skip to main content

Acute Hypoxemic Respiratory Failure: Idiopathic Pulmonary Fibrosis

  • Chapter
  • First Online:
  • 774 Accesses

Abstract

Idiopathic pulmonary fibrosis (IPF) is a disease characterized by widespread fibrotic and inflammatory abnormalities of the lung. A multidisciplinary approach is particularly important when deciding to perform additional diagnosis assessments, integrating biopsy results with clinical and CT feature. Respiratory failure is a common complication in advanced stages: oxygen supplementation and ventilator support need to be titrated according to the severity of ARF. High-Flow Nasal oxygen may be an alternative to conventional oxygen therapy in patients requiring high-flow and high oxygen concentration to correct hypoxemia and control dyspnea. Neither Non-Invasive Ventilation (NIV) nor Invasive Mechanical Ventilation (IMV) seem to change the poor outcomes associate to advanced stages of IPF, however, in selected patients, such as those with less severe ARF a NIV trial might help in the patients who may present a better short-term prognosis. More invasive techniques, including IMV and Extracorporeal Membrane Oxygenation (ECMO) should be limited to patients listed for lung transplant.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kaunisto J, Salomaa E-R, Hodgson U, Kaarteenaho R, Mylarniemi M. Idiopathic pulmonary fibrosis—a systematic review on methodology the collection of epidemiological data. BMC Pulm Med. 2013;13:53.

    Article  Google Scholar 

  2. Garcia CK. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc. 2011;8:158–62.

    Article  CAS  Google Scholar 

  3. Walsh SL, Wells AU, Desai SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med. 2016;4:557–65.

    Article  Google Scholar 

  4. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:830–6.

    Article  CAS  Google Scholar 

  5. Raghu G, Collard HP, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

    Article  Google Scholar 

  6. Raghu G, Remi-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guidelines. Am J Respir Crit Care Med. 2018;198:e44–68.

    Article  Google Scholar 

  7. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6(2):138–53.

    Article  Google Scholar 

  8. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidences, risk factors and outcome. Eur Respir J. 2011;37:356–63.

    Article  CAS  Google Scholar 

  9. Lederer D, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–23.

    Article  CAS  Google Scholar 

  10. Richeldi L, du Bois LM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

    Article  Google Scholar 

  11. Frat JP, Coudrov R, Marianovic N, Thille AW. High-flow nasal oxygen therapy and noninvasive ventilation in the management of acute hypoxemic respiratory failure. Ann Transl Med. 2017;5(14):297.

    Article  Google Scholar 

  12. Vianello A, Arcano G, Battistella L, Vio S, Concas A, et al. Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care. 2014;29:562–7.

    Article  Google Scholar 

  13. Faverio P, De Giacomi F, Sardella L, Fiorentini G, Carone M, et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm Med. 2018;18:70.

    Article  Google Scholar 

  14. Vianello A, Arcano G, Paladini L, Iovino S. Successful management of acute respiratory failure in an idiopathic pulmonary fibrosis patient using an extracorporeal carbon dioxide removal system. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:186–90.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Farris, B. (2020). Acute Hypoxemic Respiratory Failure: Idiopathic Pulmonary Fibrosis. In: Esquinas, A., Vargas, N. (eds) Ventilatory Support and Oxygen Therapy in Elder, Palliative and End-of-Life Care Patients . Springer, Cham. https://doi.org/10.1007/978-3-030-26664-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-26664-6_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-26663-9

  • Online ISBN: 978-3-030-26664-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics